Indole Carboxamide mPGES-1 Inhibitors for Selective PGE2 Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a more effective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1) that does not have the cardiovascular side effects associated with existing COX-2 inhibitors, which also effectively blocks the production of prostaglandin E2 (PGE2) to treat inflammation, arthritis, pain, and other conditions.
Innovation Solution
Development of indole carboxamide derivatives or their pharmaceutically acceptable salts, which selectively inhibit mPGES-1, thereby reducing PGE2 production without affecting other prostaglandins, using specific compounds with varying substituents on the aryl group and heterohydrocarbon rings.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX-2 inhibitors are used to reduce PGE2 production and treat inflammation, then anti-inflammatory effect is improved, but cardiovascular side effects occur due to inhibition of other prostaglandins
Solution Approach 1:
The invention segments the prostaglandin synthesis pathway by targeting a specific enzyme (mPGES-1) rather than the upstream COX-2 enzyme. This segmentation allows selective inhibition of PGE2 production while leaving other prostaglandin pathways (PGI2, TXA2) unaffected, thereby resolving the contradiction between anti-inflammatory efficacy and cardiovascular safety
Solution Approach 2:
The patent introduces mPGES-1 as an intermediary target between COX-2 and PGE2. By acting on this intermediate enzyme in the prostaglandin synthesis pathway, the invention achieves precise control over PGE2 production without disrupting other prostaglandin pathways, eliminating the harmful side effects associated with COX-2 inhibition
2Object-affected harmful factors
If mPGES-1 inhibition is pursued to achieve selective PGE2 blockade, then cardiovascular safety is improved, but more effective inhibitors need to be developed
Solution Approach 1:
The patent employs parameter changes in the chemical structure of mPGES-1 inhibitors (as shown in the various formulae with different substituents R1-R6, X1-X6) to optimize both selectivity and potency. By systematically varying molecular parameters, the invention develops inhibitors that are sufficiently effective while maintaining cardiovascular safety through selective mPGES-1 inhibition
Data Source
AI summary
Indole carboxamide compounds of Formula (II) or pharmaceutically acceptable salt thereof have activity of inhibiting production of prostaglandin E2 (PGE2) through inhibition of microsomal prostaglandin E2 synthase-1 (mPGES-1). The indole carboxamide compounds and salts can be effectively used in treating or preventing inflammation, arthritis, high fever, pain, cancer, stroke or brain diseases such as Alzheimer's disease. A pharmaceutical composition contains the indole carboxamide compound as an active ingredient.